 The investigators recently conducted a double blind, placebo controlled trial in 117 patients with non-ST segment elevation myocardial infarction NSTEMI who presented within 72 hour after the onset of chest pain. In this study, a single, intravenous dose of the IL-6 antagonist tocilizumab reduced the inflammatory activity by more than 50 in the days subsequent to the intervention. Importantly, tocilizumab also reduced troponin T TnT levels, suggesting that patients receiving tocilizumab sustained less myocardial damage than patients who received placebo.1 